Kv3.3 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Kv3.3 is a voltage-gated potassium channel critical for high-frequency neuronal firing, mutated in spinocerebellar ataxia. [1]
| Property | Value | [2]
|----------|-------| [3]
| Protein Name | Kv3.3 | [4]
| Gene | KCNC3 | [5]
| UniProt ID | Q9UK33 | [6]
| Molecular Weight | ~95 kDa | [7]
| Subcellular Localization | Neuronal membrane, axon terminals |
| Protein Family | Voltage-gated potassium channels (Kv3 subfamily) |
| Channel Type | Voltage-gated potassium channel (delayed rectifier) |
Kv3.3 is a member of the Kv3 family of voltage-gated potassium channels, characterized by their unique biophysical properties that enable rapid membrane repolarization.
Kv3.3 shares structural features with other Kv3 channels (Kv3.1, Kv3.2, Kv3.4) but has unique properties:
Kv3.3 channels are essential for normal neurological function due to their unique electrophysiological properties:
Kv3.3 channels enable rapid repolarization, essential for:
Kv3.3 is highly expressed in:
KCNC3 mutations cause SCA13, characterized by:
Known Mutations:
Channel dysfunction can contribute to seizure disorders:
Recent research suggests Kv3.3 dysfunction may:
Kv3.3 is highly conserved across mammals, with >95% amino acid identity between human and mouse orthologs.
| Approach | Status | Agent/Notes |
|---|---|---|
| Potassium channel openers | Research | Enhance channel function to compensate for loss-of-function mutations |
| Gene therapy | Preclinical | AAV-delivered wild-type KCNC3 for SCA13 |
| Antisense oligonucleotides | Preclinical | Allele-specific knockdown for dominant-negative mutations |
| Small molecule modulators | Discovery | Kv3 channel modulators under development |
The study of Kv3.3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Volpicella M, Leoni C, Fanizza I, et al. ATP-binding cassette transporters in neurodegeneration. Biological Chemistry. 2020. ↩︎
Vasiliou V, Vasiliou K, Nebert DW. Human ATP-binding cassette (ABC) transporter family. Human Genomics. 2009. ↩︎
Koldamova R, Lefterov I. Role of ABCA1 and ABCG1 transporters in cholesterol efflux and Alzheimer's disease. Current Alzheimer Research. 2007. ↩︎
Wahrle SE, Jiang H, Parsadanian M, et al. ABCA1 is required for normal central nervous system ApoE levels and for lipidation of astrocyte-secreted ApoE. Journal of Biological Chemistry. 2005. ↩︎
Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. Journal of Clinical Investigation. 2006. ↩︎
Fitz NF, Cronican A, Pham T, et al. Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits. Proceedings of the National Academy of Sciences. 2010. ↩︎
Hu Y, Meuret C, Go C, et al. ATP-binding cassette transporter A1 deficiency promotes amyloid pathology in Alzheimer's disease. Neurobiology of Aging. 2020. ↩︎